• THRBF offers an IoT- and Bluetooth-enabled device for cold-sore prevention
• Its sales strategy is part of the company’s larger focus on developing products for the dermatology market
• THRBF’s proprietary technology is designed to prevent cold sores in the OTC sector, which is projected to record significant sales growth

Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) is offering a new generation of technology in the burgeoning skin care market. The company is specifically planning to target sales growth for its high gross-margin InterceptCS* cold sore prevention device with a new website, social media campaign and online sales strategy (http://ibn.fm/qqEgF).

THRBF’s new InterceptCS is a class II medical device that works through three 30-second treatments and offers multi-use activators. Therma Bright’s strategy is to market the product online through distributors and a new social media campaign, as well as on its new website at www.ColdSores.com.

Toronto-based THRBF offers first-rate medical devices for dermatological needs. The company focuses on proprietary technology in the OTC pain-free and noninvasive sectors, and it has received class II medical device status from the U.S. Food and Drug Administration (FDA). Therma Bright also markets TherOZap, an insect-bite treatment device.

The dermatology market is estimated to reach $22.6 billion in the United States by 2028, according to GMR Data (http://ibn.fm/tzY4X).

* Based on a double-blind placebo study, InterceptCS is approved for the claim, “For prevention of cold sores when used within three hours of the onset of the prodrome,” by Health Canada. InterceptCS is not approved by the United States FDA for any claim of clinical indication, clinical efficac, and/or cure or prevention of disease.

For more information, visit the company’s website at www.ThermaBright.com

NOTE TO INVESTORS: The latest news and updates relating to THRBF are available in the company’s newsroom at http://ibn.fm/THRBF

• The R&D program will focus on the proprietary Lexaria DehydraTECH delivery technology with the purpose of enhancing it further
• Results could contribute to new patent filings in the future; in addition, the program will examine more extensively the way DehydraTECH-enabled CBD outperforms generic CBD
• Lexaria-designed nanotech enhancements will also be included in the program

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is launching its largest cannabinoid research and development program to date. The program consists of 11 separate animal studies, according to a company press release (http://ibn.fm/xidEM).

The Lexaria in vitro study design was conceptualized six months ago. Laboratory test articles have been produced and meet or exceed required quality control thresholds. The program has moved on to the implementation stage, which includes testing for a variety of performance-enhancing variations of the company’s DehydraTECH.

The DehydraTECH trademarked delivery technology is patented for cannabidiol (CBD) and tetrahydrocannabinoid (THC). The technology has a wide scope of applications, with evidence gathered separately of an ability to cross the blood-brain barrier, which could lead to applications related to nervous system conditions like Alzheimer’s disease.

Through the research, Lexaria aims to enhance the DehydraTECH drug delivery platform even further, with optimization enhancement designed to improve the platform’s performance in next-generation formulations currently under development.

As per the official Lexaria announcement, the research and development program could contribute to additional patent filings in the future. Thus, the company has limited information about the study’s design for the time being. The primary aim of the research, however, is to determine the mechanisms by which DehydraTECH-enabled CBD outperforms generic CBD – a fact that has already been established through multiple trials.

DehydraTECH and the other Lexaria technologies are already disrupting the cannabis edibles industry. These developments reduce the undesirable taste of CBD products, eliminate the need for the addition of sweeteners (simplifying the creation of sugar-free options), increase absorption rates and reduce the time of positive effect onset.

Lexaria-designed nanotech enhancements will also be included among the research and development program subjects. In the beginning of 2018, Lexaria evaluated a number of nanotech emulsions for use with DehydraTECH. These nano emulsions are expected to be tested in combination with the DehydraTECH delivery system for the first time ever.

Various nanotech solutions are already available on the market. No other company, however, has come up with a combination of nano emulsions and a drug delivery platform that’s patented for use with cannabinoids. Lexaria representatives believe that the combination enhances the individual performance characteristics of both technologies.

DehydraTECH is a disruptive delivery technology platform that promotes healthier ingestion methods and lower dosages, while increasing overall effectiveness of lipophilic active molecules. Lexaria Bioscience Corp. has multiple patents pending in over 40 countries and already has patents granted in the U.S. and Australia for the utilization of its signature DehydraTECH technology. The technology increases intestinal absorption rates, allowing for more rapid delivery to the bloodstream of various orally administered bioactive compounds, such as cannabinoids, vitamins and non-steroid anti-inflammatory drugs.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Marijuana Company of America Inc. recently initiated a new push into tetrahydrocannabinol (THC) product development through an LOI with Natural Plant Extract of California
• Analysts predict that California’s cannabis market will reach $5.1 billion in sales this year and $7.7 billion by 2022
• Recreational use marijuana is expected to be the prime driver in the market

During a crucial year for expansion in California’s cannabis market, Marijuana Company of America Inc. (OTCQB: MCOA) is lighting the pathway toward achieving its goal of farm-to-consumer vertical collaboration among its subsidiaries in the cannabis space.

MCOA recently uplisted its trading tier to the OTCQB Venture Marketplace, as well as improving its hempSMART brand presence as cannabidiol (CBD) oils and infused products gain increasing gravitas among the health and wellness community.

This month, the company added a push into the tetrahydrocannabinol (THC) product space by announcing an LOI with Natural Plant Extract of California (“NPE”) and its subsidiary, Northern Lights Distribution, LLC, to establish a joint venture that would operate a California cannabis delivery service named Viva Buds.

“This partnership will enable MCOA to establish itself as a major player in the Cannabis arena,” CEO Donald Steinberg stated in a news release about the agreement (http://ibn.fm/UZuHW). “The NPE team has a great deal of industry knowledge and has an industry disruptive business model. This is a huge strategic move for MCOA!”

Although California is more than a year into its legalization of recreational marijuana use, regulatory differences between the state’s local community markets can make getting cannabis products to consumers challenging. At the same time, the ongoing federal view of cannabis as a restricted plant has limited transportation contracts to companies that don’t have federal contracts, leaving the door open to potential competition in the space such as the proposed Viva Buds delivery service.

Data analysts at industry advisory firm Cannabis Business Plan are forecasting a California cannabis market with $7.7 billion in annual sales by 2022, with 61.5 percent of the overall market driven by recreational use marijuana (http://ibn.fm/KMTNr). Researchers at BDS Analytics predict that sales of cannabis will hit $5.1 billion in California this year due to the fast-moving nature of what is one of the largest cannabis markets in the world (http://ibn.fm/SjxCl). California tax and fee regulators are already celebrating the nearly $350 million in sales and excise tax receipts brought in during the first year of recreational marijuana legalization in the state, even though expectations had been for almost double that amount (http://ibn.fm/ED7tE).

Marijuana Company of America has seen its expectations for a cannabis boom enhanced by regulatory changes in the United States, such as the passage of the 2018 Farm Bill just ahead of year’s end, which allowed hemp to be classified as an agricultural product and paved the way for it to become a farm commodity largely free of drug schedule restrictions, even though components of the plant used for medicinal purposes still have to abide by Food and Drug Administration standards to be approved (http://ibn.fm/pORXr).

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Sales grew by more than $64 million since December 2017 launch of products
• SHRV CEO credits ‘Blue Ocean Strategy’, along with Elepreneur and Elevacity Global subsidiaries, for record performance
• Name change reflects company’s international growth strategy

Sharing Services Global Corporation (OTCQB: SHRV) reported sales of $25.9 million for its fiscal Q3 2018 ended January 31, 2019. Those numbers are $8 million higher than the $17.9 million in revenue reported in the previous quarter (http://ibn.fm/yflX1). SHRV CEO John “JT” Thatch said that the increase was due in part to the company’s implementation of a ‘Blue Ocean Strategy’ in its direct selling market. The company also announced that it has changed its name to Sharing Services Global Corporation to better reflect its international growth strategy (http://ibn.fm/YXZDY).

“Our 2018 Q3 results are continued proof that our ‘Blue Ocean Strategy’ is being implemented and accepted in the direct-selling marketplace,” Thatch said in a news release (http://ibn.fm/07NBw). “At a record-breaking pace, our Elepreneur division continues to execute on our mission to change the direct-selling industry with best-in-class products and services.” SHRV sales have grown by more than $64 million since the December 2017 launch of products through its Elepreneur and Elevacity Global divisions.

SHRV is a Plano, Texas-based diversified holdings company that owns, operates or controls a variety of companies engaged in direct selling through independent sales representatives. It also offers services such as energy, technology and insurance. Its divisions include Elevacity Global LLC and Elepreneur LLC.

In a 14A SEC filing, SHRV said that its recent name change would more accurately reflect the company’s international expansion moves (http://ibn.fm/ChZIB). The company said in the filing that it was planning to grow both organically and by making strategic acquisitions of businesses and technologies. “The company believes there are excellent growth opportunities outside the United States, including in Canada, Mexico, Europe and Asia,” the filing reads.

For more information, visit the company’s website at www.SHRVInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRV are available in the company’s newsroom at http://ibn.fm/SHRV

• 7ACRES cultivation facility’s increase in space set to grow production capacity by 50 percent, reaching approximately 26,250 kg
• BMO Capital Market analysts initiated coverage of The Supreme Cannabis Company at Market Perform
• The company is set to launch its line of premium cannabis oil products in April 2019

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a leading company in the cannabis industry that’s committed to providing premium brands and products, is seeking to grow the world’s best cannabis and become a leader in the global industry. As legalization spreads around the world, the cannabis industry continues to evolve from a market once limited to illicit recreational activity into one marked by innovative products utilized for myriad purposes, including medicinal, pharmaceutical, and health and wellness applications. Investors are realizing the lucrative potential of cannabis products, and companies such as The Supreme Cannabis Company are poised to become industry leaders.

Recently BMO Capital Markets analysts Tamy Chen, CFA, and Peter Sklar, CPA, initiated coverage of The Supreme Cannabis Company at Market Perform. This included a C$2.50 per share price target, which represented a 15 percent premium to the then-current market price. Given more brand development, the analysts anticipate a potential C$3.00 share price (http://ibn.fm/b75iI), especially with “accelerating sales, ramping production, and strategic international acquisitions.”

The Supreme Cannabis Company anticipates reaching multiple milestones this year. As of March 2019, the company has amassed growing room space of 180,000 square feet at its 7ACRES cultivation facility. This growth will enable production capacity to increase by 50 percent, reaching approximately 26,250 kg (http://ibn.fm/79ykL). Additionally, supply agreements are in place throughout eight Canadian provinces. As such, the company’s target goals continue to increase to match its evolving production capacity, which could potentially reach approximately 50,000 kg in the near future.

Supreme Cannabis president and founder John Fowler noted the significance of the company’s increased facility square footage. He described (http://ibn.fm/j0YeB) the expansion as “a major milestone, which represents a 50 percent increase in our estimated annual production capacity. With 18 of 25 flowering rooms at 7ACRES now approved by Health Canada, production space at our facility is near the finish line.” Noting the availability of the company’s 7ACRES brand in eight of 10 Canadian provinces, Fowler stated that he looks forward to serving “what [company leaders] believe to be the highest quality cannabis grown at scale in the country.”

In another step to increase its industry presence, The Supreme Cannabis Company recently announced an anticipated launch of its previously detailed cannabis oil products. These products are set to be released to the adult-use consumer market in select Canadian provinces beginning in April 2019. Each bottle of oil will contain the company’s proprietary blend of highly purified cannabis oils and terpenes harvested from plants grown by 7ACRES.

Supreme Cannabis CEO Navdeep Dhaliwal believes that the company’s focus on premium cannabis will deliver a superior cannabis oil experience. He added, “Our formulation will leverage super-critical CO2 technology to produce a high-quality, purified cannabis oil,” which is then re-formulated with the naturally occurring terpenes found in 7ACRES’ high-end cannabis. The resulting oil promises consumers a premium experience (http://ibn.fm/8GnDP).

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• Green Hygienics Holdings is planning to buy a San Diego-area ranch that occupies over 824 acres of flat grassland pasture
• The company is targeting the medical and recreational-use cannabis markets in California, which combine to make up the largest legal marketplace for cannabis sales
• GRYN anticipates that it could harvest 1,200 to 1,500 pounds of hemp per acre in two growing seasons each year

Premium cannabis cultivation company Green Hygienics Holdings Inc. (OTCQB: GRYN) announced on March 18 that it has opened escrow for the purchase of a ranch property near San Diego that will provide its growing operations with over 824 acres of flat, native grassland pasture sheltered by surrounding mountains (http://ibn.fm/ws21X).

The company is targeting the California medical and adult recreational-use markets for the plant whose growing popularity has driven changes in governmental drug-use policies on a global scale during recent years. California is the world’s largest marketplace for cannabis sales, although Canada’s nationwide full legalization of the plant last year is expected to eventually give it a boost over rivals during the next decade (http://ibn.fm/WaTXc).

Green Hygienics has a long-term strategy for expanding its portfolio throughout the United States and then advancing into the global arena, growing the company in size and revenues as it builds a large cultivation and extraction center in Canada. The company’s announcement about the potential for a cultivation site in Southern California heralds a major step toward its goals.

“Given that there is the potential to harvest 1,200 to 1,500 pounds of hemp per acre, we can produce two crops per year, and the price of hemp is at an average of $50 dollars per pound, this initiative has the potential to produce significant revenues for the Company,” Vice President of Business Development Matt Dole stated in the news release announcing the planned purchase. “This will also provide a base of operations for several other equally exciting initiatives. We have been working on this property acquisition for a very long time and are excited about the possibilities it opens up for the Company.”

The Potrero Ranch property includes 294,000 square feet of outbuildings that have been constructed on a concrete slab with triple phase power, water and gas services that make the structures ideal for use as greenhouses or storage, according to the company. The main building has a large built-in cooler, as well.

The land has an abundant water supply and the soil’s pH, as well as the altitude of the property, make the site “ideal for hemp cultivation,” the news release states.

As competition in the legal cannabis space increases among publicly-backed companies, GRYN believes that the future of commercial-sized plant cultivation for both hemp and cannabis hinges on using science to control the growing environment in order to deliver premium grades of product on a consistent basis at a comparatively low price.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer
• Combination study pairing KEYTRUDA with Bria-IMT is ongoing, with initial efficacy data for the first six patients to be released at AACR Annual Meeting
• BriaCell has closed the first tranche of a previously announced non-brokered private placement, raising gross proceeds of C$750,000

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, will present an analysis of the initial efficacy data compiled during a combination study that pairs Bria-IMT, the company’s lead cellular immunotherapy candidate, with pembrolizumab (KEYTRUDA, manufactured by Merck & Co. Inc.) in advanced breast cancer. Data is now being finalized and will be shared via press release and in conjunction with BriaCell’s poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, on April 3 (http://ibn.fm/w8UEd).

“The early efficacy data of the first six patients in our Phase I/IIa study of Bria-IMT with KEYTRUDA represents an important milestone for BriaCell as a rapidly advancing company with an innovative technology,” Dr. Bill Williams, BriaCell’s president and CEO, stated in a news release. “Through the combination study, we are learning more about the mechanism of action of our novel immunotherapy, which will aid in assessment of combining Bria-IMT with other drugs, including other checkpoint inhibitors.”

BriaCell’s focus on the development of targeted immunotherapy solutions for advanced breast cancer patients has, to date, demonstrated excellent results with Bria-IMT in several clinical trials. More than 2.1 million new cases of breast cancer were documented globally in 2018, according to the Cancer Research Institute, with medical advances still lagging for treatment of advanced breast cancer patients (http://ibn.fm/jAZmB). BriaCell has already achieved proof of concept with Bria-IMT in clinical trials in advanced breast cancer, showing an outstanding safety profile, as well as excellent efficacy, as an earlier article details (http://ibn.fm/7PAV3).

BriaCell’s combination study with KEYTRUDA, which began in October 2018 and is ongoing, primarily measures synergistic effects of the combination on tumor regression and biological response. Together, Bria-IMT and KEYTRUDA, are expected to show that the combined action of the two may be greater than the sum of their individual effects in “awakening” the immune system of the patient, as the company stated in a news release.

An additional C$750,000 has been raised following the closure of the first tranche of BriaCell’s previously-announced non-brokered private placement. BriaCell intends to use the net proceeds from the offering to finance its phase IIa combination study of Bria-IMT with KEYTRUDA in advanced breast cancer; to finance its pursuit of other research opportunities; and for working capital and general corporate purposes, per a news release (http://ibn.fm/Zq7Wp).

For more information, visit the company’s website at www.BriaCell.com

NOTE TO INVESTORS: The latest news and updates relating to BCTXF are available in the company’s newsroom at http://ibn.fm/BCTXF

• The two new cannabidiol-infused coffee brands from Youngevity are expected to become available in May, allowing the company the opportunity to establish a solid presence within the expanding market
• The first brand, HempFX, will be a direct sales product, while Javalution is set to become available later in May for retail store distribution
• The company is cultivating a market that appeals to the over 100 million coffee drinkers in the U.S. who are also aware of the benefits of cannabidiol-infused beverages

The U.S. market for cannabidiol-infused beverages is expanding rapidly, with forecasts calling for a valuation of $260 million by 2022. The revenue from such products could outpace all other industry representatives, capturing almost 20 percent of the edibles market by 2022, per industry data (http://ibn.fm/mOUIV).

There are several reasons for the growing popularity of such beverages. Legalization measures in the U.S. are the first and most prominent reason why the market is anticipated to grow. In addition, consumers are becoming more conscious of healthy choices, substituting typical beverages with much more beneficial options (http://ibn.fm/oJLig).

Addressing the market dynamics and seizing the new opportunities, companies like Youngevity International Inc. (NASDAQ: YGYI) are announcing innovative developments designed to provide health-conscious customers with more options.

Youngevity is catering to a market of over 100 million Americans who drink coffee and are aware of the numerous health benefits resulting from the consumption of cannabidiol-infused beverages. In March 2019, the company announced the development and launch of two infused coffee brands.

As per the official announcement, sale of the new coffee brands is anticipated to start in May 2019. HempFX will be a direct sales product that will be available through the Youngevity distribution and sales network. Youngevity’s subsidiary, CLR Roasters, anticipates the rollout of its Javalution brand later in May for retail store distribution. The retail sales presentation for Javalution has already started (http://ibn.fm/043id).

Both of the brands will offer coffee lovers four flavor profiles – Dark Roast, Donut Shop, French Vanilla and House Blend. Each one will be available as a single-serve product that delivers 10 milligrams of cannabidiol per cup of coffee.

According to Youngevity president and CFO Dave Briskie, delivering water-soluble cannabidiol in consistent doses has been a challenge that the company managed to overcome. The currently utilized solution passes laboratory testing to ensure consistent delivery of the beverage’s cannabidiol content.

The development became possible through the work of the Youngevity team at Khrysos Global – a Florida-based manufacturer of hemp-based cannabidiol extraction equipment. Youngevity acquired Khrysos in February, gaining ownership of INX Labs and the Khrysos testing facilities.

The water-soluble cannabidiol infusion technology is deliverable in both powders and liquids. This fact provides Youngevity with the opportunity to continue exploring the cannabidiol beverage and food markets, launching new products in the future.

Youngevity International is a leading omni-direct lifestyle company that emphasizes a hybrid model of direct selling and social selling. It has been included among the top 100 global direct selling companies. Youngevity offers products in the top eight selling retail categories, which include health and nutrition, home and family, food and beverage, spa and beauty, fashion, essential oils, photo and innovative services.

For more information, visit the company’s website at www.YGYI.com

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

• The newly developed ShieldSaver app simplifies windshield changes and the selection of reputable service providers in the automotive glass industry
• In an underserved market, the app is providing customers with opportunities that were previously unavailable
• The automotive glass industry is anticipated to continue growing rapidly in the years to come after reaching $12 billion in 2017

ShieldSaver, a subsidiary of technology and investment company SinglePoint Inc. (OTCQB: SING), recently announced the launch of a new mobile app for the automotive glass space (http://ibn.fm/xyFZG). Currently, ShieldSaver is operational at Sacramento International Airport and Wally Park’s Denver International Airport.

SinglePoint acquired ShieldSaver in 2018 with the goal of disrupting the $12 billion automotive glass industry. The ShieldSaver platform went through a complete overhaul that took nine months to complete. This transformation contributed to one of the most sophisticated automotive glass space apps, as SinglePoint CEO Greg Lambrecht noted in a video interview.

According to ShieldSaver founder Dan Shikiar, the market is underserved and the new platform provides opportunities that weren’t available before. The app has the potential to expand beyond the vertical of the automotive repair market, Lambrecht added. The model for the app development mirrors the concept behind successful platforms like Airbnb and similar sales aggregators that give customers full control over the experience.

ShieldSaver gives customers access to free same-day or next-day mobile service, OEM quality glass and a lifetime warranty on workmanship. The installation is provided by certified glass technicians, and, according to the official presentation, the app ensures complete transparency. The use of the app removes the middleman from the equation, resulting in faster and, quite often, more affordable windshield replacement services than the offers provided by big competitors.

Following the launch of the ShieldSaver app, SinglePoint and ShieldSaver intend to develop a blockchain solution with the aim of appending its data. The introduction of blockchain technology is expected to simplify access to and retrieval of important information for all interested parties.

In 2017, the automotive glass market exceeded $12 billion dollars, and it is expected to grow at a CAGR of seven percent until 2024 (http://ibn.fm/8Lvcp). Some reports suggest that the automotive glass market will reach $23.59 billion by 2025. Increased vehicle production and sales, novel safety regulations and the demand for advanced glass technologies (smart glass, for example) are all projected to contribute to the massive growth (http://ibn.fm/eol9j).

To ensure consistent service provision and a solid presence in this ever-growing market, ShieldSaver has entered into strategic partnerships with some of the largest companies in the automotive glass space. The partner network features reputable names like Wally Park, Mygrant Glass, LAZ Parking and various others.

SinglePoint specializes in the acquisition of small and mid-sized companies that operate in new technological fields. These acquisitions provide opportunities for investment across a wide range of assets, including payment solutions, cannabis brands, blockchain technology developers and more. Through acquisitions into horizontal markets, SinglePoint is building a solid portfolio that ensures a rich and diversified holding base.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• PLUS received a positive rating, in part, due to its anticipated move into cannabis baked goods and mints
• PLUS is eyeing expansion into Oregon, Nevada and additional states in the future
• According to retail sales data, PLUS was California’s number one cannabis-infused edibles brand in retail sales and units sold in Q3 and Q4 2018

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) has received a ‘Speculative Buy’ rating in its initial coverage by Canaccord Genuity (“CG”), as well as a price target of C$8 (http://ibn.fm/U81qs). Driving that positive report is the company’s planned move to expand its product line of cannabis edibles, such as gummies, into baked goods and mints.

PLUS may also offer its top-selling product lines beyond California into Oregon and Nevada. The company has also alluded to future growth into other markets, such as Massachusetts, Florida, Michigan and New York. This proposed expansion comes as hemp and cannabis markets continue to flourish. As Bobby Burleson, a CG analyst, noted in the report (http://ibn.fm/N8qnW), “We see significant long-term growth opportunities for hemp-based CBD.”

CG’s report noted that gummies represent 36 percent of the cannabis edibles market in California. PLUS could gain product share, as consumers in that market have begun to trend away from buying traditional flower at dispensaries. Edibles have gained from this shift, Real Deal reported. As a result, gummies rose from 28 percent of California sales in January 2018 to almost 45 percent in January 2019.

According to BDS Analytics’ retail sales data, PLUS product lines made up the number one cannabis-infused edibles brand in retail sales and units sold in Q3 and Q4 2018 (http://ibn.fm/5haLF). CG projects that PLUS will sell 3.7 million packages in 2019, as compared to 1.4 million in 2018. CG also estimates that the company’s California market share could almost double from 8 percent in 2018 to 15 percent in 2019, reaching 28 percent in 2020, as reported by Real Money.

San Mateo, California-based PLUS is a cannabis-infused, branded products manufacturer currently selling to regulated medicinal and adult-use recreational markets exclusively in California. PLUS is focused on building the largest cannabis brand by growing organically and through acquisitions.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF